Published in Proc Natl Acad Sci U S A on January 30, 2007
Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS One (2008) 1.95
Alzheimer disease. Dis Mon (2010) 1.64
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation (2008) 1.29
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev (2008) 1.08
Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.07
Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol (2010) 1.06
Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol Disord Drug Targets (2013) 1.05
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr Alzheimer Res (2011) 1.02
Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm (Vienna) (2011) 0.99
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct (2009) 0.95
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Alternative Abeta immunotherapy approaches for Alzheimer's disease. CNS Neurol Disord Drug Targets (2009) 0.92
HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Int J Clin Exp Pathol (2008) 0.92
T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation (2014) 0.91
Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PLoS One (2013) 0.83
CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol Dis (2007) 0.83
Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol (2008) 0.82
Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease. Cardiovasc Psychiatry Neurol (2010) 0.81
AD vaccines: conclusions and future directions. CNS Neurol Disord Drug Targets (2009) 0.79
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2010) 0.78
The "brain-skin connection" in protein misfolding and amyloid deposits: embryological, pathophysiological, and therapeutic common grounds? Front Neurol (2012) 0.76
Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neurol (2012) 0.76
Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. Hum Vaccin Immunother (2014) 0.75
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Functional diversity of helper T lymphocytes. Nature (1996) 18.09
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng (2001) 4.64
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology (2005) 2.58
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol (2000) 2.08
Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci (2005) 1.99
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci (2002) 1.97
Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol (2001) 1.95
Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci (2003) 1.88
Needle-free vaccine delivery. Adv Drug Deliv Rev (2006) 1.80
Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci (2006) 1.79
Mouse lymphoid tissue contains distinct subsets of langerin/CD207 dendritic cells, only one of which represents epidermal-derived Langerhans cells. J Invest Dermatol (2005) 1.78
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci (2006) 1.51
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
T-cells in Alzheimer's disease. Neuromolecular Med (2005) 1.38
Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity (2003) 1.29
Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J (2006) 1.25
Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett (2001) 1.23
TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol (2006) 1.22
Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res (2006) 1.17
T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun (2001) 1.15
Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging (2002) 1.15
CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci (2000) 1.14
Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect Immun (2003) 1.13
Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol (2002) 1.13
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Int Immunol (2005) 0.98
Immune response modifiers--mode of action. Exp Dermatol (2006) 0.97
Hapten-specific tolerance induced by acute, low-dose ultraviolet B radiation of skin is mediated via interleukin-10. J Invest Dermatol (1997) 0.95
Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection. Vaccine (2005) 0.95
Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses. Immunology (2006) 0.90
T cells from epicutaneously immunized mice are prone to T cell receptor revision. Proc Natl Acad Sci U S A (2005) 0.89
Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiol Dis (2006) 0.87
Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine (2005) 0.86
Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother (2005) 0.86
Genetic background determines susceptibility to experimental immune-mediated blepharoconjunctivitis: comparison of Balb/c and C57BL/6 mice. Exp Eye Res (2005) 0.86
Vaccines for Alzheimer's disease: how close are we? CNS Drugs (2003) 0.86
Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine (2005) 0.82
Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines. Eur J Immunol (2005) 0.82
A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Vet Immunol Immunopathol (2005) 0.80
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med (2004) 7.49
Interchromosomal associations between alternatively expressed loci. Nature (2005) 7.45
A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol (2009) 5.26
Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity (2012) 5.08
Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity (2007) 4.07
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med (2008) 3.15
Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). J Clin Psychiatry (2010) 2.89
Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology (2007) 2.82
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J (2005) 2.30
The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation (2005) 2.23
Primary cilia regulate hippocampal neurogenesis by mediating sonic hedgehog signaling. Proc Natl Acad Sci U S A (2008) 2.17
Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc (2006) 2.12
Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med (2006) 2.11
Compositional gradients in Gramineae genes. Genome Res (2002) 2.04
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Correlation of cavitation with ultrasound enhancement of thrombolysis. Ultrasound Med Biol (2006) 2.00
Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci (2005) 1.99
Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem (2004) 1.99
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci (2002) 1.97
Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis (2009) 1.91
Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol (2005) 1.90
Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol (2002) 1.89
Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci (2006) 1.79
Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci (2003) 1.76
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
New insights into chimpanzees, tools, and termites from the Congo Basin. Am Nat (2004) 1.71
Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice. J Clin Invest (2004) 1.67
Malignant minor pleural effusion detected on thoracotomy for patients with non-small cell lung cancer: is tumor resection beneficial for prognosis? Ann Thorac Surg (2002) 1.66
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
Microglia recognize double-stranded RNA via TLR3. J Immunol (2006) 1.60
Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol (2004) 1.58
Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest (2007) 1.57
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation (2005) 1.57
Polymorphism of antigen MPT64 in Mycobacterium tuberculosis strains. J Clin Microbiol (2013) 1.56
Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice. Cancer Chemother Pharmacol (2009) 1.54
Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis (2010) 1.52
Prospective study of extended segmentectomy for small lung tumors: the final report. Ann Thorac Surg (2002) 1.48
TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 1.48
Fabrication of Graphene/Polyaniline Composite Paper via In Situ Anodic Electropolymerization for High-Performance Flexible Electrode. ACS Nano (2009) 1.47
RNA interference-mediated downregulation of hypoxia-inducible factor-1α inhibits angiogenesis and survival of oral squamous cell carcinoma in vitro and in vivo. Eur J Cancer Prev (2012) 1.45
Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis. J Neurol (2011) 1.44
Crystal structure of the HCV IRES central domain reveals strategy for start-codon positioning. Structure (2011) 1.44
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther (2011) 1.43
CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol (2009) 1.43
MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett (2011) 1.42
Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci (2010) 1.42
Applicability of blunt renal trauma classification of Japanese Association for the Surgery of Trauma (JAST). Int J Urol (2009) 1.41
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol (2008) 1.41
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Pachyonychia congenita with corneal dystrophy. J Dermatol (2013) 1.39
T-cells in Alzheimer's disease. Neuromolecular Med (2005) 1.38
CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol (2005) 1.38
Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia (2004) 1.37
Ziprasidone-induced oculogyric crisis. J Am Acad Child Adolesc Psychiatry (2003) 1.37
Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res (2008) 1.35
IL-10 signaling blockade controls murine West Nile virus infection. PLoS Pathog (2009) 1.35
Genome sequence of the date palm Phoenix dactylifera L. Nat Commun (2013) 1.35
Efficient calculation of configurational entropy from molecular simulations by combining the mutual-information expansion and nearest-neighbor methods. J Comput Chem (2008) 1.35
Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci (2005) 1.34
Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol (2007) 1.32
Functional reconstitution of human eukaryotic translation initiation factor 3 (eIF3). Proc Natl Acad Sci U S A (2011) 1.30
Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J (2010) 1.30
Ruptured hepatic abscess caused by fish bone penetration of the duodenal wall: report of a case. Surg Today (2007) 1.30
Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation (2008) 1.29
West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J Immunol (2007) 1.26
Toll-like receptor modulation of murine cerebral malaria is dependent on the genetic background of the host. J Infect Dis (2007) 1.25
Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis (2010) 1.25
Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One (2012) 1.24